RankAlpha logo
Back to Rankings

IART

Integra LifeSciencesB
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case after earnings is straightforward: Q1 beat prior-year levels, margins improved, full-year adjusted EPS guidance moved higher, and Tissue Reconstruction showed better momentum helped by Integra Skin, PriMatrix, and Durepair. If the end-June SurgiMend production target is met, investors may start paying for a cleaner 2026-2027 recovery path.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.6.
What can break
Net debt of about $1.6 billion and leverage of 4.1x reduce room for operational misses.
Momentum
95
Value
52
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.50 · Bull $17.00 · Bear $10.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.29
Why
Momentum95 · Δ7d +0.6
Value52 · Δ7d -0.1
Sentiment38 · Δ7d -0.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
34% active weight
Current posture
7d trendSoftening
Δ7d
+0.6
Δ21d
+8.0
Value
52
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
38
33% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-3.6
Why this grade

Composite grade B. Momentum 94.8 / Value 52.0 / Sentiment 38.0

Fundamentals (TTM)
As of 2026-05-29
Market Cap
$1.25B
Beta
1.04
Shares Out
77.89M
P/E (TTM) · Derived
-2.4
P/S (TTM)
0.60
P/FCF (TTM)
65.17
Rev YoY
+5.6%
EPS YoY
+49.7%
Gross Margin
+57.2%
Op Margin
-29.3%
Net Debt
$1.53B
Current Ratio
3.14
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology